Study on CCR2 PET Imaging for Head and Neck Squamous Cell Carcinoma
Sponsor: Washington University School of Medicine
Sponsor score: 40
ClinicalTrials ID:NCT07659678
This clinical trial is testing a new imaging method using Cu-64 DOTA-ECL1i PET/CT scans to see how well it can detect head and neck squamous cell carcinoma (HNSCC).
Patient Parameters
| Parameter | Options |
|---|
Program Overview
The purpose of this study is to evaluate a new imaging technique called Cu-64 DOTA-ECL1i PET/CT to determine its accuracy in identifying head and neck squamous cell carcinoma (HNSCC). This imaging method aims to provide precise images that can help in diagnosing and planning treatment for patients with this type of cancer.
Eligibility Criteria
Inclusion Criteria
- Adults aged 18 or older.
- For Cohort 1: Patients with newly diagnosed advanced head and neck squamous cell cancer scheduled for surgery, with or without prior therapy.
- For Cohort 2: Patients with suspected or confirmed recurrent or metastatic head and neck cancer scheduled for first-line anti-PD1 therapy.
- Tumor size must be at least 1.0 cm in the longest dimension on standard imaging.
- Must be able to provide informed consent.
- Women must not be pregnant or nursing and must meet specific criteria regarding reproductive status, such as being surgically sterile, post-menopausal, or having a negative pregnancy test before the study.
Exclusion Criteria
- Patients with other invasive cancers, except for non-melanoma skin cancer, if they have had any evidence of the other cancer within the last 2 years.
- Patients who cannot tolerate about 60 minutes of PET/CT imaging.
Locations
| FACILITY | ZIP | CITY | STATE |
|---|---|---|---|
| Washington University School of Medicine | 63110 | St Louis | Missouri |
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.